Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
about
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control studyThe Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western CountriesThe Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in ChinaRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivistDysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesisHigh basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitisClassification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosisPathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitisCranial nerve palsy in Wegener's granulomatosis--lessons from clinical cases.Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinineDevelopment and initial evaluation of a measure of self-management for adults with antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.Health-related quality of life for patients with vasculitis and their spouses.Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis.Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.Management of ANCA-associated vasculitis: Current trends and future prospectsBK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans.High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestationsWhat Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis PopulationValidation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcomeCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabSuccessful induction of granulomatosis with polyangiitis with tacrolimus.Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvementDetection of autoantibodies in a point-of-care rheumatology setting.Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease.Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.Presence of neutrophil extracellular traps and antineutrophil cytoplasmic antibodies associated with vasculitides.ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse.Notes on the kidney and its diseases for the neurologist.Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides.Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis
P2860
Q23922033-BC05D96B-9AEE-4172-987D-B6715E96A2ECQ26740451-ECF8DDFF-C608-4AD9-A5BE-7AA67D57D0FEQ26740453-D2C1E762-4908-459A-8933-CCF4A1CBCEA8Q26751357-AE1F4A6A-5A09-4A22-AFEB-0FDA8C1E88C0Q27025692-8885AA20-0F79-495F-ABD7-135820484B11Q27485164-652140BB-90CF-4FF1-9DA4-8C438E381C8AQ28386922-96116AA2-476E-4216-AD88-735F25BABEF4Q28387176-AA388960-1861-402B-AE86-6948D75619C5Q28389271-3E0E8B0B-EEE1-4661-9368-2700576388D9Q28389895-AABDDB16-7967-404C-8CC8-302E6AE6F66FQ33413841-A09C689C-8D0D-43FB-BF26-1B758D92D919Q33420968-71FB35DA-600D-4015-9F4F-AA56F6588F3CQ33571802-8D2DF0E7-71FF-4FF7-9C5D-87E6A4E91B8BQ33697927-65CF062C-2C18-4750-8EE8-D434BC48E13DQ33726893-06E8EB13-551A-4810-86BC-4006D37696A1Q33731434-D4D1BF75-CEE0-425E-AB1E-7FDFACEE434EQ33771970-A4AAC61C-FCA4-42CE-9E4C-C7E58A787CF5Q33784256-32D6B1CC-A2F7-4686-8659-C544F82ED1F4Q33862188-2452466E-89DD-4AC0-8F6D-381B53A32F2EQ33947599-D1FC251B-1E79-486A-B0E4-5C62F259808CQ34081869-0B0AFAE6-0795-4DDB-839C-BA7EFC7AF305Q34187707-B2AAB00C-9891-4716-B0A0-37E0A0A84518Q34500661-256E9EB3-2C08-4C62-AA91-08765763EF4CQ34971461-62D7E0B0-193A-44EA-B573-CCAE517FDDCFQ35007874-1EFB01DA-145B-4E64-8C3A-963B7AB3E5FAQ35065425-855ECE9A-2F6F-40F9-A8D1-4A6E7B7A6DDFQ35071121-1FBD1032-89A7-4C7C-8CF4-7CDAF2CBF678Q35228543-91B5A528-ABC7-4696-9D68-EA2BD3E20366Q35309576-F8F467F9-76C7-4E5A-B105-F48C0304ED53Q35662018-2422F1A9-88AE-4E05-8C8D-A96B3033C621Q35724221-A150D99D-10CE-49D2-99AE-A8580C6151A8Q35758533-147147C7-DEB7-4EA9-B9E5-55E2A78918EDQ35798078-E238E1EA-5683-40C8-8FD1-21DDB43AED02Q35810445-8A902CB9-DA59-49BE-8B63-3A3E394EE65EQ35999786-071D8A0E-3178-473E-994E-A6356421502EQ36223713-6367370F-D4AC-475C-852D-C5DEDF5DE232Q36227382-DB8332D9-2190-4DFB-9489-42946D22AA4CQ36332824-1CB9D5A7-E8C4-4DEC-8C1B-6B3D3FB7E7B4Q36535223-07C78E69-1F2A-480F-BC6F-B409438E60A4Q36583330-7DE1DC25-461F-4BE5-92F2-B7012E06E402
P2860
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@en
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@nl
type
label
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@en
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@nl
prefLabel
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@en
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@nl
P2093
P1476
Predictors of relapse and trea ...... iated small-vessel vasculitis.
@en
P2093
Caroline E Jennette
Hyunsook Chin
J Charles Jennette
Jianwen Cai
Patrick H Nachman
Ronald J Falk
Susan L Hogan
P304
P356
10.7326/0003-4819-143-9-200511010-00005
P407
P577
2005-11-01T00:00:00Z